Aktualne metody farmakologicznego leczenia łagodnego przerostu prostaty u psów

• Autorzy: Pasikowska J. , Nizanski W.

Warianty tytułu

EN

Methods of pharmacological treatment of benign prostatic hyperplasia in dogs: An update

• Języki publikacji: PL

Abstrakty

EN

Benign prostatic hyperplasia (BPH) is the most common disease of the prostate in dogs. It can be treated by surgical or pharmacological methods. Surgical methods are used in non-breeder males or males with pathological changes in the testis. Pharmacological treatment is an alternative for breeder males and old animals with associated diseases. Substances that can be used for medical treatment are GnRH analogues, GnRH antagonists, estrogens, progestogens, antiandrogens, inhibitors of 5α-reductase, antiestrogens, and VDR agonists. This paper presents short characteristics of pharmacological substances that we have used in BPH treatment.

Słowa kluczowe

PL

psy; samce; choroby gruczolu krokowego; lagodny przerost gruczolu krokowego; objawy chorobowe; leczenie; leczenie farmakologiczne; leki; agonisci receptorow GnRH; antagonisci receptorow GnRH; progestageny; antyandrogeny; inhibitory 5alfa-reduktazy; agonisci receptora wotaminy D; zastosowanie; skutecznosc; dzialanie uboczne

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2015
• Tom: 71
• Numer: 06
• Opis fizyczny: s.335-340,bibliogr.

Twórcy

autor

Pasikowska J.

• Katedra Rozrodu z Kliniką Zwierząt Gospodarskich, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy we Wrocławiu, pl.Grunwaldzki 49, 50-366 Wrocław

autor

Nizanski W.

• Katedra Rozrodu z Kliniką Zwierząt Gospodarskich, Wydział Medycyny Weterynaryjnej, Uniwersytet Przyrodniczy we Wrocławiu, pl.Grunwaldzki 49, 50-366 Wrocław

Bibliografia

• 1. Adrioni L., Penna G., Amuchastegui S., Cossetti Ch., Aquilano F., Mariani R., Fibbi B., Morelli A., Ukokovic M., Colli E., Maggi M.: Inhibition of prostategrowth and inflammation by the vitamin D receptor agon sit BXL-628 (elocalcitol).J. Steroid. Biochem. Mol. Biol. 2007, 103, 689-693.
• 2. Albouy M., Sanquer A., Maynard L., Eun H. N.: Efficacies of osaterone and delmadinone in treatment of benign prostatic hyperplasia in dogs. Vet. Rec. 2008, 163, 179-183.
• 3. Brook Ch., Marshall N.: Podstawy endokrynologii. Wydawnictwo Medyczne Urban&Partner, Wrocław 2002.
• 4. Corrada Y., Arias D., Rodriguez R., Spaini E., Fava F., Gobello C.: Effect of tamoxifen citrate on reproductive parameters of male dogs. Theriogenology2004, 61, 1327-1341.
• 5. Court E. A., Watson A. D., Church D. B., Emslie D. R.: Effects of delmadinone acetate on pituitary-adrenal function, glucose tolerance and growth hormonein male dogs. Aust. Vet. J. 1998, 76, 555-560.
• 6. Crescioli C., Ferruzzi P., Caporali A., Mancina R., Comerci A., Muratori M., Scaltriti M., Vanelli G. B., Smiroldo S., Mariani R., Villari D., Bettuzzi S.,Serio M., Adrioni L., Maggi M.: Inhibition of spontaneous and androgen-inducedprosatate growth by a nonhypercalcemic calcitriol analog.Endocrinology 2003, 144, 3046-3057.
• 7. Crescioli C., Maggi M., Vannelli G. B., Luconi M., Salerno R., Barni T., Gulisano M., Forti G., Serio M.: Effect of a vitamin D3 analoque on keratinocytegrowth factor-induced cell proliferation in BPH. J. Clin. Endocrionol.Metab. 2000, 85, 2576-2583.
• 8. Flanagan C. A., Millar R. P., Illing N.: Advances in under standing gonadotrophin-releasing hormone receptor structure and ligand interactions. J. Reprod.Fertil. 1997, 2, 113-120.
• 9. Fontaine E., Fontbonne A.: Clinical Use of GnRH Agonists in Canine and Feline Species. Reprod. Dom. Anim. 2011, 46, 344-353.
• 10. Giziński S., Dabrowski M., Domino M.: Kastracja chirurgiczna psów a występowanie i rozwój raka gruczołu krokowego. Mag. Wet. 2014, 203, 272-277.
• 11. Gobello C.: Dopamine agonists, anti-progestins, anti-androgens, long-termrelease GnRH agonists and anti-estrogens in canine reproduction: A review. Therigenology 2006, 66, 1560-1567.
• 12. Gobello C., Corrada Y.: Noninfectious Prostatic Diseases In Dogs. Compendium of Continuing Education for The Practicing Veterinarian 2002, 2,99-107.
• 13. Goericke-Pesch S., Wilhelm E., Ludwig C., Desmoulins P. O., Driancourt M. A., Hoffmann B.: Evaluation of the clinical efficacy of Gonazon implants in thetreatment of reproductive pathologies, behavioral problems and suppressionof reproductive function in the male dog. Theriogenology 2010, 73, 920-926.
• 14. Johnston S. D., Kamolpatana K., Root-Kustritz M. V., Johnston G. R.: Prostatic disorders in dog. Anim. Reprod. Sci. 2000, 60-61, 405-415.
• 15. Johnston S. D., Kustritz M. V., Olson P. N. S.: Canine and feline therigenology. Saunders 2001.
• 16. L’Eplattenier H. F.: Studies on the pathogenesis and management of prostate carcinoma in dogs. Dissertation, Utrecht University 2009.
• 17. Lepor H.: The role of gonadotropin-realising hormone antagonist for treatment of bening prostatic hyperplasia. Reviews in urology 2006, 8, 4, 183-189.
• 18. Limmanont Ch., Phavaputanon J., Sirinarumitr K.: Effect of Finasteride and Deslorelin Treatment on Clinical Signs, Prostatic Volume and Semen Qualityin Dog with Benign Prostatic Hypetrophy: A clinical Trial. Kasetsart J. Nat.Sci. 2012, 46, 724-735.
• 19. Lu N. Z., Wardell S. E., Burnstein K. L., Defranco D., Fuller P. J., Giguere V., Hochberg R. B., McKay L., Renoir J. M., Weigel N. L., Wilson E. M., McDonell D. P., Cidlowski J. A.: International Union of Pharmacology. LXV. The Pharmacology and Classification of the Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen Receptors.Pharmacol. Rev. 2006, 58, 782-797.
• 20. McArdle C. A., Davidson J. S., Willars G. B.: The tail of the gonadotrophin-releasing hormone receptor: desensitization AT, and distal to, G protein-coupled receptors. Moll. Cell. Endocrinol. 1999, 151, 129-136.
• 21. McArdle C. A., Franklin J., Green L., Hislop J. N.: Signalling, cycling and desensitisation of gonadotrophin-releasing hormnone receptors. J. Endocrinol.2002, 173, 1-11.
• 22. McConnell J. D.: The Pathophysiology of Benign Prostatic Hyperplasia. Journal of Andrology 1991, 6, 356-363.
• 23. McCoy A. C.: Tamoxifen: Mechanism of Resistance. The University of Tennessee Health Science Center 2010.
• 24. McLeod D. G.: Antiandrogenic drugs. Cancer 1993, 1, 1046-1049.
• 25. Minato K., Koizumi N., Honma S., Tsukamoto K., Iwamura S.: Pharmacokinetics and biliary excretion of osaterone acetate, a New steroid al antiandrogen, indogs. Drug Metab. Dispos. 2002, 30, 167-172.
• 26. Riesenbeck A., Klein R., Hoffmann B.: Downregulation, a new and reversible approach to eliminate testicluar function in the dog. Der Prakt. Tierarzt 2002, 83, 512-520.
• 27. Romagnoli S.: Two common cases of infertility in the Male dog. 31st World Small Animal Veterinary Congress. Czechy, Praga 2006.
• 28. Romero G., Vliente C., Aquilano D., Corrada Y., Gobello C.: Endocrine effects of the GnRH antagonist, acyline in domestic dogs. Theriogenology 2009, 71,1234-1237.
• 29. Shimizu M., Tsutsui T., Kawakami E., Hori T., Fujita M., Orima H., Ogasa A.: Effect of chlormadinone acetate-pellet implantation on the volume of prostate,peripheral blood levels of sex hormones and semen quality in the dog. J. Vet.Med. Sci. 1995, 57, 395-399.
• 30. Sukcharoen N.: GnRH Antagonists: an Update. Thai Journal of Obstetrics and Gynaecology 2000, 12, 71-76.
• 31. Trębacz P., Galanty M.: Kiedy i dlaczego leczymy farmakologicznie gruczoł krokowy u psów. Życie Wet. 2008, 83, 280-284.
• 32. Trigg T. E., Wright P. J., Armour A. F., Wiliamson P. E., Junaidi A., Martin G. B., Doyle A. G., Walsh J.: Use of GnRH analoque implant to produce long--term supression of reproductive function of Male and female domestic dogs.J. Reprod. Fertil. 2001, 57, 255-261.
• 33. Tsutsui T., Hori T., Shimizu M., Orima H., Kawakami E., Fukuda S.: Regression of Prostatic Hypertrophy by Osaterone Acetate in Dogs. J. Vet. Med. Sci. 2000,62, 10, 1115-1119.
• 34. Tsutsui T., Hori T., Shimizu M., Tatsuzawa C., Kawakami E.: Effect of Osaterone Acetate Administration on Prostatic Regression Rate, Peripheral Blood Hormone Levels and Semen Quality in Dogs with Benign Prostatic Hypertrophy. J. Vet. Med. Sci. 2001, 63, 453-456.
• 35. Zambelli D., Cunto M., Gentilini F.: Validation of a model to develop a symptom index for Benin prostatic hyperplasia in dogs. Reprod. Dom. Anim. 2012, 47, 229-231.